Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon-Alpha2a + Ruxolitinib in Newly Diagnosed Polycythemia Vera
2024-518216-39-00Phase 2Authorised
- Sponsor
- Region Zealand
- Start
- Nov 2024
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of interferon alfa and ruxolitinib in polycythemia vera (PV), sponsored by Region Zealand. Primary endpoint: Safety profile. Planned start Nov 2024; status: authorised.
02
Drugs
interferon alfaruxolitinib
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on 2024-518216-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518216-39-00.